MRVI — Maravai Lifesciences Holdings Share Price
0.000.00%
Last trade - 00:00- $1.48bn
- $1.74bn
- $185.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.09% | ||
| Return on Equity | -40.83% | ||
| Operating Margin | -82.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 799.24 | 883 | 288.94 | 259.19 | 185.74 | 210.43 | 225.85 | -8.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +462.29 | +13.93 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.
Directors
- Carl Hull CHM (63)
- Eric Tardif PRE (52)
- Kevin Herde CFO (49)
- Kurt Oreshack GCN (41)
- Christine Dolan OTH (53)
- Brian Neel OTH (45)
- Lisa Sellers OTH (49)
- Sean Cunningham DRC (45)
- Benjamin Daverman DRC (43)
- Luke Marker DRC (36)
- Constantine Mihas DRC (54)
- Anat Ashkenazi IND (48)
- Susannah Gray IND (60)
- Robert Hance IND (61)
- Jessica Hopfield IND (56)
- Gregory Lucier IND (57)
- Murali Prahalad IND (49)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- August 25th, 2020
- Public Since
- November 20th, 2020
- No. of Shareholders
- 3
- No. of Employees
- 416
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 295,012,328
- Address
- 10770 Wateridge Circle Suite 200, SAN DIEGO, 92121
- Web
- https://www.maravai.com/
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Upcoming Events for MRVI
Q3 2026 Maravai LifeSciences Holdings Inc Earnings Release
Similar to MRVI
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Maravai Lifesciences Holdings share price?
As of Today at 21:54 UTC, shares in Maravai Lifesciences Holdings are trading at $5.02. This share price information is delayed by 15 minutes.
How has the Maravai Lifesciences Holdings share price performed this year?
Shares in Maravai Lifesciences Holdings last closed at $5.02 and the price had moved by +131.34% over the past 365 days. In terms of relative price strength the Maravai Lifesciences Holdings share price has outperformed the S&P500 Index by +87.99% over the past year.
What are the analyst and broker recommendations for Maravai Lifesciences Holdings?
The overall consensus recommendation for Maravai Lifesciences Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Maravai Lifesciences Holdings dividend yield?
Maravai Lifesciences Holdings does not currently pay a dividend.
Does Maravai Lifesciences Holdings pay a dividend?
Maravai Lifesciences Holdings does not currently pay a dividend.
When does Maravai Lifesciences Holdings next pay dividends?
Maravai Lifesciences Holdings does not currently pay a dividend.
How do I buy Maravai Lifesciences Holdings shares?
To buy shares in Maravai Lifesciences Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Maravai Lifesciences Holdings?
As of the previous close price of $5.02, shares in Maravai Lifesciences Holdings had a market capitalisation of $1.48bn.
Where are Maravai Lifesciences Holdings shares listed?
Here are the trading details for Maravai Lifesciences Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MRVI
What kind of share is Maravai Lifesciences Holdings?
Based on an overall assessment of its quality, value and momentum Maravai Lifesciences Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Maravai Lifesciences Holdings share price forecast for 2026?
The analyst consensus target price for shares in Maravai Lifesciences Holdings is $5.70. That is 13.55% above the last closing price of $5.02.
Analysts covering Maravai Lifesciences Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.11 for the next financial year.
Find out moreWhat is the trend in the Maravai Lifesciences Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Maravai Lifesciences Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +25.8%.
As of the last closing price of $5.02, shares in Maravai Lifesciences Holdings were trading +48.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Maravai Lifesciences Holdings PE Ratio?
The Maravai Lifesciences Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Maravai Lifesciences Holdings?
Maravai Lifesciences Holdings' management team is headed by:
- Carl Hull - CHM
- Eric Tardif - PRE
- Kevin Herde - CFO
- Kurt Oreshack - GCN
- Christine Dolan - OTH
- Brian Neel - OTH
- Lisa Sellers - OTH
- Sean Cunningham - DRC
- Benjamin Daverman - DRC
- Luke Marker - DRC
- Constantine Mihas - DRC
- Anat Ashkenazi - IND
- Susannah Gray - IND
- Robert Hance - IND
- Jessica Hopfield - IND
- Gregory Lucier - IND
- Murali Prahalad - IND